Practice of Epidemiology Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort
暂无分享,去创建一个
P. Gustafson | Yinshan Zhao | J. Petkau | M. E. Karim | H. Tremlett | E. Kingwell | M. L. van der Kop | J. Oger | A. Shirani | M. Kop | C. Evans
[1] P. Gustafson,et al. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study , 2014, European journal of neurology.
[2] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[3] R. Ali,et al. On computing standard errors for marginal structural Cox models , 2014, Lifetime data analysis.
[4] Michal Abrahamowicz,et al. Comparison of Approaches to Weight Truncation for Marginal Structural Cox Models , 2013 .
[5] P. Gustafson,et al. Interferon beta and long-term disability in multiple sclerosis. , 2013, JAMA neurology.
[6] E. Frohman,et al. Interferon beta and long-term disability in multiple sclerosis--reply. , 2013, JAMA neurology.
[7] P. Calabresi,et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. , 2013, JAMA neurology.
[8] W G Havercroft,et al. Simulating from marginal structural models with time‐dependent confounding , 2012, Statistics in medicine.
[9] J. Petkau,et al. Treatment With Interferon Beta for Multiple Sclerosis—Reply , 2012 .
[10] D. Goodin,et al. Treatment with interferon beta for multiple sclerosis. , 2012, JAMA.
[11] S. Cole,et al. A simulation study of finite‐sample properties of marginal structural Cox proportional hazards models , 2012, Statistics in medicine.
[12] Wei Zhong,et al. Assessing mediation using marginal structural models in the presence of confounding and moderation. , 2012, Psychological methods.
[13] P. Gustafson,et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.
[14] L. Kappos,et al. Evaluating the potential benefit of interferon treatment in multiple sclerosis. , 2012, JAMA.
[15] Stephen R Cole,et al. Estimating the Effects of Multiple Time-varying Exposures Using Joint Marginal Structural Models: Alcohol Consumption, Injection Drug Use, and HIV Acquisition , 2012, Epidemiology.
[16] S. Cole,et al. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. , 2012, American journal of epidemiology.
[17] Edward A. Smith,et al. Introducing the At-Risk Average Causal Effect with Application to HealthWise South Africa , 2012, Prevention Science.
[18] Samy Suissa,et al. The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding , 2012, European Journal of Epidemiology.
[19] M. J. van der Laan,et al. Colon Cancer Survival With Herbal Medicine and Vitamins Combined With Standard Therapy in a Whole-Systems Approach , 2011, Integrative cancer therapies.
[20] M. J. van der Laan,et al. Lung Cancer Survival With Herbal Medicine and Vitamins in a Whole-Systems Approach , 2011, Integrative cancer therapies.
[21] Hansjakob Furrer,et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time‐dependent confounding applied to data from the Swiss HIV Cohort Study , 2010, Statistics in medicine.
[22] D. Goodin,et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[23] S. Cole,et al. Time scale and adjusted survival curves for marginal structural cox models. , 2010, American journal of epidemiology.
[24] Michal Abrahamowicz,et al. The International Journal of Biostatistics CAUSAL INFERENCE Accuracy of Conventional and Marginal Structural Cox Model Estimators : A Simulation Study , 2011 .
[25] F. Dekker,et al. The International Journal of Biostatistics Comparing Mortality in Renal Patients on Hemodialysis versus Peritoneal Dialysis Using a Marginal Structural Model , 2011 .
[26] Jessica G. Young,et al. Relation between three classes of structural models for the effect of a time-varying exposure on survival , 2010, Lifetime data analysis.
[27] S. Cole,et al. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. , 2010, American journal of epidemiology.
[28] Yinshan Zhao,et al. Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.
[29] J. Robins,et al. Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.
[30] Stephen R Cole,et al. Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.
[31] J. Fisk,et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? , 2007, Neurology.
[32] S. Suissa,et al. Immortal time bias in the study of effectiveness of interferon‐β in multiple sclerosis , 2008, Annals of neurology.
[33] Yinshan Zhao,et al. Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[34] G. Filippini,et al. Interferon‐β treatment and the natural history of relapsing‐remitting multiple sclerosis , 2008, Annals of neurology.
[35] M. Trojano,et al. New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .
[36] J. Robins,et al. Estimating causal effects from epidemiological data , 2006, Journal of Epidemiology and Community Health.
[37] D. Paty,et al. Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.
[38] Jay S. Kaufman,et al. Methods in social epidemiology , 2006 .
[39] M. Glymour,et al. USING CAUSAL DIAGRAMS TO UNDERSTAND COMMON PROBLEMS IN SOCIAL EPIDEMIOLOGY , 2006 .
[40] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.
[41] A. Alheraish,et al. Design and implementation of home automation system , 2004, IEEE Transactions on Consumer Electronics.
[42] M. J. van der Laan,et al. Analysis of longitudinal marginal structural models. , 2004, Biostatistics.
[43] M. Hernán,et al. Controlling for Time-dependent Confounding using Marginal Structural Models , 2004 .
[44] James M. Robins,et al. Association, Causation, And Marginal Structural Models , 1999, Synthese.
[45] J. Robins,et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.
[46] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[47] S. Cole,et al. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. , 2002, American journal of epidemiology.
[48] James M Robins,et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.
[49] J. Robins,et al. Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .
[50] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[51] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[52] D. Berry,et al. Statistical models in epidemiology, the environment, and clinical trials , 2000 .
[53] James M. Robins,et al. Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .
[54] Evidence of interferon β-1a dose response in relapsing-remitting MS , 1999, Neurology.
[55] D. Rubin,et al. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. Commentary. Authors' reply , 1999 .
[56] G. Shaw,et al. Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .
[57] Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. , 1999, Neurology.
[58] J. Pearl,et al. Causal diagrams for epidemiologic research. , 1999, Epidemiology.
[59] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[60] Terry M. Therneau,et al. Extending the Cox Model , 1997 .
[61] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[62] Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. , 1995, Neurology.
[63] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[64] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[65] R B D'Agostino,et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. , 1990, Statistics in medicine.
[66] D. Paty,et al. Scales for rating impairment in multiple sclerosis , 1988, Neurology.
[67] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[68] Richard D. Gill,et al. Understanding Cox's regression model: a martingale approach : (preprint) , 1984 .
[69] W. A. Thompson,et al. On the treatment of grouped observations in life studies. , 1977, Biometrics.
[70] D. Horvitz,et al. A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .